Share
array:23 [
"pii" => "S2013251424001342"
"issn" => "20132514"
"doi" => "10.1016/j.nefroe.2024.07.003"
"estado" => "S300"
"fechaPublicacion" => "2024-07-01"
"aid" => "1165"
"copyrightAnyo" => "2024"
"documento" => "article"
"crossmark" => 1
"subdocumento" => "rev"
"cita" => "Nefrologia (English Version). 2024;44:465-74"
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"Traduccion" => array:1 [
"es" => array:18 [
"pii" => "S021169952300067X"
"issn" => "02116995"
"doi" => "10.1016/j.nefro.2023.04.006"
"estado" => "S300"
"fechaPublicacion" => "2024-07-01"
"aid" => "1165"
"documento" => "article"
"crossmark" => 1
"subdocumento" => "rev"
"cita" => "Nefrologia. 2024;44:465-74"
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"es" => array:13 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>"
"titulo" => "Documento de información y consenso para el manejo diagnóstico y terapéutico del prurito asociado a la enfermedad renal crónica en pacientes en hemodiálisis en España"
"tienePdf" => "es"
"tieneTextoCompleto" => "es"
"tieneResumen" => array:2 [
0 => "es"
1 => "en"
]
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "465"
"paginaFinal" => "474"
]
]
"titulosAlternativos" => array:1 [
"en" => array:1 [
"titulo" => "Information and consensus document for the diagnostic and therapeutic management of pruritus associated with chronic kidney disease in patients on haemodialysis in Spain"
]
]
"contieneResumen" => array:2 [
"es" => true
"en" => true
]
"contieneTextoCompleto" => array:1 [
"es" => true
]
"contienePdf" => array:1 [
"es" => true
]
"resumenGrafico" => array:2 [
"original" => 0
"multimedia" => array:7 [
"identificador" => "fig0005"
"etiqueta" => "Figura 1"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr1.jpeg"
"Alto" => 4341
"Ancho" => 3164
"Tamanyo" => 950446
]
]
"descripcion" => array:1 [
"es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Algoritmo de manejo diagnóstico y terapéutico del Pa-ERC en pacientes en hemodiálisis.</p>"
]
]
]
"autores" => array:1 [
0 => array:2 [
"autoresLista" => "Juan Manuel Buades, Ignasi Figueras-Nart, Marian Goicoechea, Rafael Jesús Sánchez Villanueva, Esther Serra-Baldrich"
"autores" => array:6 [
0 => array:2 [
"nombre" => "Juan Manuel"
"apellidos" => "Buades"
]
1 => array:2 [
"nombre" => "Ignasi"
"apellidos" => "Figueras-Nart"
]
2 => array:2 [
"nombre" => "Marian"
"apellidos" => "Goicoechea"
]
3 => array:2 [
"nombre" => "Rafael Jesús"
"apellidos" => "Sánchez Villanueva"
]
4 => array:2 [
"nombre" => "Esther"
"apellidos" => "Serra-Baldrich"
]
5 => array:1 [
"colaborador" => "en representación del Grupo Español de Prurito Asociado a ERC"
]
]
]
]
]
"idiomaDefecto" => "es"
"Traduccion" => array:1 [
"en" => array:9 [
"pii" => "S2013251424001342"
"doi" => "10.1016/j.nefroe.2024.07.003"
"estado" => "S300"
"subdocumento" => ""
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"idiomaDefecto" => "en"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251424001342?idApp=UINPBA000064"
]
]
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021169952300067X?idApp=UINPBA000064"
"url" => "/02116995/0000004400000004/v1_202407151348/S021169952300067X/v1_202407151348/es/main.assets"
]
]
"itemSiguiente" => array:19 [
"pii" => "S201325142400155X"
"issn" => "20132514"
"doi" => "10.1016/j.nefroe.2024.07.005"
"estado" => "S300"
"fechaPublicacion" => "2024-07-01"
"aid" => "1173"
"copyright" => "Sociedad Española de Nefrología"
"documento" => "article"
"crossmark" => 1
"subdocumento" => "rev"
"cita" => "Nefrologia (English Version). 2024;44:475-85"
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"en" => array:13 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
"titulo" => "Nomenclature in Palliative and Kidney Supportive Care: Not Just at the End-of-Life"
"tienePdf" => "en"
"tieneTextoCompleto" => "en"
"tieneResumen" => array:2 [
0 => "en"
1 => "es"
]
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "475"
"paginaFinal" => "485"
]
]
"titulosAlternativos" => array:1 [
"es" => array:1 [
"titulo" => "Nomenclatura en cuidados paliativos y de soporte renal: no solo al final de la vida"
]
]
"contieneResumen" => array:2 [
"en" => true
"es" => true
]
"contieneTextoCompleto" => array:1 [
"en" => true
]
"contienePdf" => array:1 [
"en" => true
]
"resumenGrafico" => array:2 [
"original" => 0
"multimedia" => array:8 [
"identificador" => "fig0005"
"etiqueta" => "Fig. 1"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr1.jpeg"
"Alto" => 1535
"Ancho" => 2500
"Tamanyo" => 273175
]
]
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0005"
"detalle" => "Fig. "
"rol" => "short"
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Structure of palliative care in patients with advanced chronic kidney disease.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">CKD G5: grade 5 chronic kidney disease (refers to cases with a glomerular filtration rate that drops below 15 ml/min/1.73 m<span class="elsevierStyleSup">2</span>); KRT: kidney replacement therapy: comprehensive conservative care, synonymous with conservative kidney management (CKM).</p>"
]
]
]
"autores" => array:1 [
0 => array:2 [
"autoresLista" => "Lina Nitola-Mendoza, Miguel Sánchez-Cárdenas, Néstor Rodriguez-Chitiva, José María Mora Gutiérrez, Rosely Rodriguez-Pena, Gregorio Romero-González, Monserrat Bleda Pérez, Paula Cuenca Casbas, Agnès Calsina-Berna, Margarita Álvaro-Pardo, Virginia Granados Casas, Paula Garrido Ballart, Patricia Beroiz Groh, Jordi Bover, Ramón Miralles Basseda, Juan Pablo Leiva-Santos, Alberto Alonso-Babarro, Joaquim Julià-Torras"
"autores" => array:18 [
0 => array:2 [
"nombre" => "Lina"
"apellidos" => "Nitola-Mendoza"
]
1 => array:2 [
"nombre" => "Miguel"
"apellidos" => "Sánchez-Cárdenas"
]
2 => array:2 [
"nombre" => "Néstor"
"apellidos" => "Rodriguez-Chitiva"
]
3 => array:2 [
"nombre" => "José María"
"apellidos" => "Mora Gutiérrez"
]
4 => array:2 [
"nombre" => "Rosely"
"apellidos" => "Rodriguez-Pena"
]
5 => array:2 [
"nombre" => "Gregorio"
"apellidos" => "Romero-González"
]
6 => array:2 [
"nombre" => "Monserrat"
"apellidos" => "Bleda Pérez"
]
7 => array:2 [
"nombre" => "Paula"
"apellidos" => "Cuenca Casbas"
]
8 => array:2 [
"nombre" => "Agnès"
"apellidos" => "Calsina-Berna"
]
9 => array:2 [
"nombre" => "Margarita"
"apellidos" => "Álvaro-Pardo"
]
10 => array:2 [
"nombre" => "Virginia"
"apellidos" => "Granados Casas"
]
11 => array:2 [
"nombre" => "Paula"
"apellidos" => "Garrido Ballart"
]
12 => array:2 [
"nombre" => "Patricia"
"apellidos" => "Beroiz Groh"
]
13 => array:2 [
"nombre" => "Jordi"
"apellidos" => "Bover"
]
14 => array:2 [
"nombre" => "Ramón"
"apellidos" => "Miralles Basseda"
]
15 => array:2 [
"nombre" => "Juan Pablo"
"apellidos" => "Leiva-Santos"
]
16 => array:2 [
"nombre" => "Alberto"
"apellidos" => "Alonso-Babarro"
]
17 => array:2 [
"nombre" => "Joaquim"
"apellidos" => "Julià-Torras"
]
]
]
]
]
"idiomaDefecto" => "en"
"Traduccion" => array:1 [
"es" => array:9 [
"pii" => "S0211699523000759"
"doi" => "10.1016/j.nefro.2023.05.006"
"estado" => "S300"
"subdocumento" => ""
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"idiomaDefecto" => "es"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699523000759?idApp=UINPBA000064"
]
]
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S201325142400155X?idApp=UINPBA000064"
"url" => "/20132514/0000004400000004/v1_202408300447/S201325142400155X/v1_202408300447/en/main.assets"
]
"itemAnterior" => array:19 [
"pii" => "S2013251424001627"
"issn" => "20132514"
"doi" => "10.1016/j.nefroe.2024.08.001"
"estado" => "S300"
"fechaPublicacion" => "2024-07-01"
"aid" => "1207"
"copyright" => "Sociedad Española de Nefrología"
"documento" => "article"
"crossmark" => 1
"subdocumento" => "sco"
"cita" => "Nefrologia (English Version). 2024;44:459-64"
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"en" => array:11 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
"titulo" => "Individualisation and challenges for haemodialysis in the next decade"
"tienePdf" => "en"
"tieneTextoCompleto" => "en"
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "459"
"paginaFinal" => "464"
]
]
"titulosAlternativos" => array:1 [
"es" => array:1 [
"titulo" => "Individualización y desafíos para la hemodiálisis de la próxima década"
]
]
"contieneTextoCompleto" => array:1 [
"en" => true
]
"contienePdf" => array:1 [
"en" => true
]
"resumenGrafico" => array:2 [
"original" => 0
"multimedia" => array:8 [
"identificador" => "fig0005"
"etiqueta" => "Fig. 1"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr1.jpeg"
"Alto" => 1402
"Ancho" => 2508
"Tamanyo" => 267339
]
]
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0005"
"detalle" => "Fig. "
"rol" => "short"
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Schematic representation of the main care of the hemodialysis patient.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">VA: vascular access; A/B: acid-base; BioIM: bioimpedance; BioM: biomarkers of congestion; PE: physical examination; eKt/V: equilibrated Kt/V urea; CKD: chronic kidney disease; ACKD: advanced chronic kidney disease; Kt: sitting clearance; BMM: bone-mineral metabolism; nPCR: normalized protein catabolism rate; PoCUS: Point-of- care ultrasonography; std Kt/V: standard weekly Kt/V.</p>"
]
]
]
"autores" => array:1 [
0 => array:2 [
"autoresLista" => "Itziar Castaño, Gregorio Romero-González, Marta Arias, Almudena Vega, Javier Deira, Pablo Molina, Raquel Ojeda, Francisco Maduell"
"autores" => array:9 [
0 => array:2 [
"nombre" => "Itziar"
"apellidos" => "Castaño"
]
1 => array:2 [
"nombre" => "Gregorio"
"apellidos" => "Romero-González"
]
2 => array:2 [
"nombre" => "Marta"
"apellidos" => "Arias"
]
3 => array:2 [
"nombre" => "Almudena"
"apellidos" => "Vega"
]
4 => array:2 [
"nombre" => "Javier"
"apellidos" => "Deira"
]
5 => array:2 [
"nombre" => "Pablo"
"apellidos" => "Molina"
]
6 => array:2 [
"nombre" => "Raquel"
"apellidos" => "Ojeda"
]
7 => array:2 [
"nombre" => "Francisco"
"apellidos" => "Maduell"
]
8 => array:1 [
"colaborador" => "En nombre del grupo de trabajo de Hemodiálisis en centro"
]
]
]
]
]
"idiomaDefecto" => "en"
"Traduccion" => array:1 [
"es" => array:9 [
"pii" => "S0211699523001443"
"doi" => "10.1016/j.nefro.2023.09.003"
"estado" => "S300"
"subdocumento" => ""
"abierto" => array:3 [
"ES" => true
"ES2" => true
"LATM" => true
]
"gratuito" => true
"lecturas" => array:1 [
"total" => 0
]
"idiomaDefecto" => "es"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699523001443?idApp=UINPBA000064"
]
]
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251424001627?idApp=UINPBA000064"
"url" => "/20132514/0000004400000004/v1_202408300447/S2013251424001627/v1_202408300447/en/main.assets"
]
"en" => array:21 [
"idiomaDefecto" => true
"cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
"titulo" => "Information and consensus document for the diagnostic and therapeutic management of pruritus associated with chronic kidney disease in patients on haemodialysis in Spain"
"tieneTextoCompleto" => true
"paginas" => array:1 [
0 => array:2 [
"paginaInicial" => "465"
"paginaFinal" => "474"
]
]
"autores" => array:1 [
0 => array:4 [
"autoresLista" => "Juan Manuel Buades, Ignasi Figueras-Nart, Marian Goicoechea, Rafael Jesús Sánchez Villanueva, Esther Serra-Baldrich"
"autores" => array:6 [
0 => array:3 [
"nombre" => "Juan"
"apellidos" => "Manuel Buades"
"referencia" => array:2 [
0 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">a</span>"
"identificador" => "aff0005"
]
1 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">g</span>"
"identificador" => "aff0035"
]
]
]
1 => array:3 [
"nombre" => "Ignasi"
"apellidos" => "Figueras-Nart"
"referencia" => array:3 [
0 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">c</span>"
"identificador" => "aff0015"
]
1 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">d</span>"
"identificador" => "aff0020"
]
2 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">e</span>"
"identificador" => "aff0025"
]
]
]
2 => array:4 [
"nombre" => "Marian"
"apellidos" => "Goicoechea"
"email" => array:1 [
0 => "marian.goicoechea@gmail.com"
]
"referencia" => array:3 [
0 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">f</span>"
"identificador" => "aff0030"
]
1 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">g</span>"
"identificador" => "aff0035"
]
2 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">*</span>"
"identificador" => "cor0005"
]
]
]
3 => array:3 [
"nombre" => "Rafael Jesús"
"apellidos" => "Sánchez Villanueva"
"referencia" => array:2 [
0 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">b</span>"
"identificador" => "aff0010"
]
1 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">g</span>"
"identificador" => "aff0035"
]
]
]
4 => array:3 [
"nombre" => "Esther"
"apellidos" => "Serra-Baldrich"
"referencia" => array:3 [
0 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">d</span>"
"identificador" => "aff0020"
]
1 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">e</span>"
"identificador" => "aff0025"
]
2 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">h</span>"
"identificador" => "aff0040"
]
]
]
5 => array:2 [
"colaborador" => "en representación del Grupo Español de Prurito Asociado a ERC"
"referencia" => array:1 [
0 => array:2 [
"etiqueta" => "<span class="elsevierStyleSup">1</span>"
"identificador" => "fn0005"
]
]
]
]
"afiliaciones" => array:8 [
0 => array:3 [
"entidad" => "Servicio de Nefrología, Hospital Universitario de Son Llàtzer, Institut d’Investigació Sanitària IIles Balears (IdISBa), Palma de Mallorca, Spain"
"etiqueta" => "a"
"identificador" => "aff0005"
]
1 => array:3 [
"entidad" => "Servicio de Nefrología, Hospital Universitario La Paz, Madrid, Spain"
"etiqueta" => "b"
"identificador" => "aff0010"
]
2 => array:3 [
"entidad" => "Servicio de Dermatología, Hospital Universitari de Bellvitge, Barcelona, Spain"
"etiqueta" => "c"
"identificador" => "aff0015"
]
3 => array:3 [
"entidad" => "Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC), Spain"
"etiqueta" => "d"
"identificador" => "aff0020"
]
4 => array:3 [
"entidad" => "International forum for the study of itch (IFSI), Spain"
"etiqueta" => "e"
"identificador" => "aff0025"
]
5 => array:3 [
"entidad" => "Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain"
"etiqueta" => "f"
"identificador" => "aff0030"
]
6 => array:3 [
"entidad" => "Sociedad Española de Nefrología, Spain"
"etiqueta" => "g"
"identificador" => "aff0035"
]
7 => array:3 [
"entidad" => "Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
"etiqueta" => "h"
"identificador" => "aff0040"
]
]
"correspondencia" => array:1 [
0 => array:3 [
"identificador" => "cor0005"
"etiqueta" => "⁎"
"correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>."
]
]
]
]
"titulosAlternativos" => array:1 [
"es" => array:1 [
"titulo" => "Documento de información y consenso para el manejo diagnóstico y terapéutico del prurito asociado a la enfermedad renal crónica en pacientes en hemodiálisis en España"
]
]
"resumenGrafico" => array:2 [
"original" => 0
"multimedia" => array:8 [
"identificador" => "fig0005"
"etiqueta" => "Fig. 1"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr1.jpeg"
"Alto" => 4341
"Ancho" => 3164
"Tamanyo" => 987215
]
]
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0005"
"detalle" => "Fig. "
"rol" => "short"
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Algorithm for diagnostic and therapeutic management of Pa-CKD in hemodialysis patients.</p>"
]
]
]
"textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Pruritus associated with chronic kidney disease (Pa-CKD) is one of the most common and disabling comorbidities in patients with advanced CKD.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–3</span></a> In Spain, between 51% and 59% of hemodialysis patients suffer from Pa-CKD.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4–6</span></a> In addition, it is associated with a higher risk of mortality, worse quality of life, sleep disorders, mental health disorders and greater use of health resources.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,7</span></a> The clinical presentation of Pa-CKD is very heterogeneous, making it difficult to diagnose and treat.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,8</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Currently, there are no specific guidelines for the management of Pa-CKD. At the European level, there is only the "European S2K Guideline on chronic pruritus" developed by the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV).<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> This guideline provides summarized evidence on therapeutic options for the different types of chronic pruritus (including Pa- CKD), and for each of the therapeutic options; an evidence-based expert recommendation is provided. Currently, there is no consensus on the most appropriate diagnostic and treatment algorithm for Pa- CKD.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> In Spain, Pa-CKD is mainly treated by nephrology specialists; however, the clinical practice guidelines for CKD published by the different Spanish nephrology societies do not include the management of Pa- CKD.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The lack of specific therapeutic options for Pa-CKD promotes the lack of consensus guidelines for diagnosis and treatment, which, in turn, leads to under-diagnosis of Pa-CKD and a suboptimal therapeutic approach.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In April 2022, the European Medicines Agency (EMA) authorized the first drug indicated for Pa-CKD, difelicefalin, which has been shown to be effective in the treatment of Pa-CKD in two Phase 3 clinical trials (KALM-1 and KALM-2) (12-week duration) and in the additional 52-week open-label extension study in hemodialysis patients.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> The reduction in pruritus intensity translates into substantial long-term improvements in patients' health-related quality of life (HRQoL), as demonstrated in KALM-1 and its open-label extension (OLE) phase. In both studies (KALM-1 and KALM-2), a significantly higher proportion of patients treated with difelicefalin achieved an improvement of ≥3 points on the WI-NRS scale over placebo. Patients in the difelicefalin group during the double-blind phase also experienced sustained improvement in pruritus and in their HRQoL (5-D Itch Scale and Skindex-10). In addition, patients who received placebo in the double-blind phase and difelicefalin in the KALM-1 OLE had a mean change of 6.9 (95% CI −7.7 to −6.2) points on the 5-D Itch Scale from baseline to week 52 of the OLE phase.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Difelicefalin is administered 3 times a week by rapid intravenous injection into the venous line of the dialysis circuit at the end of the hemodialysis treatment, during or after pumping the blood back to the patient. Thanks to its form of administration, at the end of the hemodialysis session, difelicefalin does not place an additional burden of visits on the patient, so it has a high potential for compliance. Moreover, it does not require additional monitoring, which simplifies its use. The recommended dose of difelicefalin is 0.5 µg/kg dry body weight (i.e., target weight after dialysis). The total dose volume (ml) required from the vial should be calculated as follows: 0.01 × dry body weight (kg), rounded to the nearest one-tenth (0.1 ml) (see data sheet).<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Thanks to the development of a specific drug for Pa-CKD with robust evidence on its efficacy and safety, the doors have been opened to greater knowledge and awareness of this pathology.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The aim of this consensus document is to provide national recommendations for the updated diagnostic and therapeutic management of Pa-CKD for hemodialysis patients.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Methodology</span><p id="par0040" class="elsevierStylePara elsevierViewall">Physicians specialized in nephrology and dermatology have participated in the development of the algorithm. To this end, several virtual coordination, discussion and consensus meetings have been held.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Based on an initial working outline, the experts divided the recommendations to be made into three sections: differential diagnosis, assessment of the severity of Pa-CKD and treatment of pruritus, which were subsequently reviewed and discussed by the entire group.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Each proposed recommendation was finalized after a literature search and, to a large extent, supported by the experience and opinions of experts. Once the final version of the algorithm had been validated by the entire Spanish Pruritus Group and dermatology specialists, the final document was drafted.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Following approval of the algorithm, the document has been submitted for public review by members of the Spanish Society of Nephrology (SENEFRO).</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Results</span><p id="par0060" class="elsevierStylePara elsevierViewall">The diagnostic and treatment algorithm for Pa-CKD is presented in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>. The recommendations developed by the group of experts are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Screening</span><p id="par0065" class="elsevierStylePara elsevierViewall">The questionnaires used for the diagnosis and assessment of the severity of pruritus (KDQoL-36 and WI-NRS and SADS, respectively) have been selected because they are simple to understand and easy to answer or being fulfilled by the patient.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13–16</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">With regard to the diagnosis of chronic pruritus, it was decided to use only question 20 of the KDQoL-36 for the initial screening, since the answer obtained provides relevant and sufficient information for the screening: "In the last 4 weeks, to what extent have you felt discomfort caused by itching" (and as answers: none, some, quite a lot, a lot or very much). In this way, the presence and intensity of itching can be screened quickly and easily. This initial screening should be performed by the nephrology or nursing professional. If the patient responds "somewhat, quite a lot, a lot or very much" a differential diagnosis will be made by the nephrologist to rule out other possible causes. This screening will be performed every 3 months in patients in whom Pa-CKD has not been diagnosed.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Differential diagnosis</span><p id="par0075" class="elsevierStylePara elsevierViewall">The following explains how to perform the differential diagnosis. First of all, it is necessary to verify whether or not skin lesions are present. These could be primary or secondary (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). Although primary lesions are not attributable to Pa-CKD, secondary lesions may be related. To rule out the presence of such lesions not attributable to Pa-CKD, it is necessary to perform a skin examination of the patient, ideally in the consultation room in order to maintain the patient's privacy. It is also recommended to consult with the dermatologist. For more information on the type of lesions, see Appendix Annex 2. In case of presence of skin lesions not attributable to Pa-CKD, these should be treated by the dermatologist. In case no lesions are visualized or these are secondary, other potential causes of active pruritus in the patient should also be ruled out (e.g., hematological disease, liver/bile disease, neurological disease, psychiatric disease, neoplasia, drugs). In the case of other possible causes, the patient will be referred to the corresponding specialist to receive the most appropriate treatment. Finally, the diagnosis of Pa-CKD should be considered if there are no primary lesions or other causes associated with pruritus. It should be noted that, in the case of xerosis, despite being a primary lesion, it could coexist with Pa-CKD.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">Once a potential patient has been identified, an assessment of the intensity and severity of pruritus is made using the WI-NRS and SADS questionnaires (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>). Patients should complete the WI-NRS questionnaire daily for one week, or at least 3 days in one week. For the evaluation of the results, the average of the evaluations of all days will be taken. Patients who obtain a mean score ≥4 points on the WI-NRS and categories B or C on the SADS will be categorized as patients with moderate-severe pruritus (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Registration</span><p id="par0085" class="elsevierStylePara elsevierViewall">If the patient is diagnosed with Pa-CKD, the healthcare professional involved should register it as a health problem or diagnosis in a structured and systematized manner. To do this, the detailed medical history of any patient with chronic pruritus should be collected first. This should include the general characteristics of the pruritus (e.g., duration, time course, location, intensity and quality), knowledge of the patient's medical history, including accurate information on medication changes in the last year and family history, as well as the performance of a complete dermatological examination.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Pathology coding is used to record the pathology in the computer system. To do this, it is necessary to classify and assign a specific code to this pathology.</p><p id="par0095" class="elsevierStylePara elsevierViewall">Currently, in the international disease classification systems 9 and 10 (ICD-9 and ICD-10) there are no specific codes for Pa-CKD, but the disease classification system 11 (ICD-11), which will be implemented in hospitals in the coming years, does incorporate specific codes for Pa-CKD (EC90.1). Until ICD-11 is available, it is recommended that Pa-CKD be coded with the tools currently available (ICD-9, ICD-10), as shown in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>, indicating in the clinical history the association of pruritus with CKD. It is also possible to perform a direct mapping (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>), so when implemented in the hospitals of the National Health System it will improve the system of registration and diagnosis of patients with Pa-CKD.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,17,18</span></a></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">In the SNOMED CT terminology there is also a specific code for Pa-CKD: 403733004 - "Hemodialysis-associated pruritus",<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> which could also be used in hospitals where it is in effect.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Treatment and follow-up</span><p id="par0105" class="elsevierStylePara elsevierViewall">Regarding the treatment of pruritus, patients with Pa-CKD will receive one or another therapy depending on the severity. For mild Pa-CKD, general measures will be used, such as skin hydration and maintenance of the barrier function (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>) and other skin care techniques, as well as other methods to reduce pruritus (<a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>). In addition, adequate dialysis efficacy and control of calcium-phosphorus metabolism should be ensured. In case the patient has moderate to severe pruritus (WI-NRS ≥4 or SADS B or C), specific itch therapy is recommended, with difelicefalin being the only drug with specific indication approved for Pa-CKD in hemodialysis patients. Difelicefalin is not yet marketed in Spain<a class="elsevierStyleCrossRef" href="#fn0010"><span class="elsevierStyleSup">1</span></a>. Since it is currently only available intravenously and in clinical trials it has been administered at the end of the hemodialysis session, it can only be applied to hemodialysis patients. Other off-label options to consider include gabapentinoids, mirtazapine and/or montelukasts. In a systematic review, 6 of the 7 included studies reported favorable results in decreasing Pa-CKD after gabapentin administration. However, it should be noted that the number of patients included in these studies is limited and most of them are under 65 years of age.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19,20</span></a> In addition, important side effects have been reported, so the healthcare professional should consider the risk/benefit profile before using them (<a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a>). Likewise, it should be taken into account that the use of gabapentinoids requires dose adjustments and monitoring; furthermore, there are safety alerts and problems of dependence, abuse and withdrawal syndrome in several countries (United States, United Kingdom, France and Spain).<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21–24</span></a> Another drug such as montelukast, a leukotriene receptor antagonist used in the treatment of asthma, allergic rhinitis, atopic dermatitis and idiopathic urticaria has shown favorable results in the reduction of Pa-CKD in 2 randomized placebo-controlled studies.<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25,26</span></a> However, as in the gabapentin studies, the number of patients in the 2 montelukast studies is limited and the mean age of patients is below 65 years, while the mean age of hemodialysis patients is mostly above 65.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> Mirtazapine is a serotonergic antagonist with antihistamine action that demonstrated efficacy in reducing the intensity of pruritus in a clinical trial with 77 patients treated initially with gabapentin and subsequently with mirtazapine.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> Finally, for refractory pruritus, phototherapy is recommended. However, it should be noted that there is currently no clinical evidence on the combination of treatments.</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><p id="par0110" class="elsevierStylePara elsevierViewall">Once treatment for Pa-CKD has been initiated, it is necessary to follow up the intensity of pruritus (by passing the WI-NRS and SADS questionnaires) at least at 3 months. If there are severe side effects or no improvement after 3 months, re-evaluation of treatment at this time could be considered. It should be considered that with some drugs the effect may not be immediate, and the results are maximized after the first 2 weeks, so it would not be recommended to abandon treatment before such an effect can be observed. However, dermatology specialists recommend taking the WI-NRS questionnaire daily/periodically, as far as possible, in order to observe the effect of the treatment continuously.</p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Discussion</span><p id="par0115" class="elsevierStylePara elsevierViewall">To date, diagnostic guidelines for Pa-CKD are scarce. There is no globally accepted method or diagnostic guideline for measuring Pa-CKD. Furthermore there is not a specific diagnostic code for Pa-CKD in ICD-10.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> This generates a situation of underdiagnosis and underreporting, resulting in global prevalence data of Pa-CKD between very wide ranges.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> It is necessary to promote the specific coding of Pa-CKD in order to have accurate data on these parameters in Spain.</p><p id="par0120" class="elsevierStylePara elsevierViewall">There are no specific guidelines for Pa-CKD in Spain, and the CKD treatment guidelines do not include the management of Pa-CKD. This makes the therapeutic approach dissimilar and not optimized, highlighting a clear unmet need for this pathology.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,29,30</span></a> Internationally, the German S2K guidelines for the diagnosis and treatment of chronic pruritus recommend difelicefalin as the first treatment option for moderate or severe Pa-CKD in hemodialysis patients.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">The perception of most Spanish nephrologists (91%) is that presently the Pa-CKD is an unsolved problem due mainly to the low efficacy of the therapeutic options available to date; this was reflected in a survey conducted through the SEN in 2021.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> In this analysis a16% of nephrologists stated that the prevalence of pruritus in their center was greater than 20%, while 84% considered the current prevalence to be 10–20%.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> However, in the survey conducted by the SEN in the framework of Pruritus Week,it was reported a prevalence of Pa-CKD of 50.5% of hemodialysis patients, being moderate to severe in 26.7%.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0130" class="elsevierStylePara elsevierViewall">In Spain, there is still a long way to go before ICD-11 is implemented, since most hospitals have the previous versions ICD-9 and ICD-10, which prevents proper coding of the Pa-CKD and, therefore, its recording is incorrect.</p><p id="par0135" class="elsevierStylePara elsevierViewall">In the nationwide survey conducted by Alcer (Association for the Fight Against Kidney Diseases), 26% of hemodialysis patients with Pa-CKD reported that never felt an improvement in their quality of life with the treatment received for pruritus. A 35% of hemodialysis patients with Pa-CKD claimed not to have expressed their itching symptoms to any health professional, of which 26% explained that the reason was the belief that they would not give it importance, 23% because they thought it had no solution and 20% because they did not know that it could be related to CKD.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">The introduction of new specific treatments for Pa-CKD opens a new horizon for improving the quality of life of these patients. In the nation wide survey, it was observed that 44% of hemodialysis patients with Pa-CKD claimed to feel irritability more than once a week due to pruritus; 32% frustration; 21% anguish and 11% depression.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">An article by Agarwal et al. published in August 2022, explains how understanding of the pathophysiology of a particularly bothersome symptom of hemodialysis (Pa-CKD) led to the design, development, and regulatory approval of a treatment for that symptom. It highlights the importance to patients of improving itching symptoms and quality of life, and proposes an algorithm for the screening, diagnosis, assessment and treatment of Pa-CKD among hemodialysis patients, taking into account the introduction of the only drug approved for this pathology, difelicephalin.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">32</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">The diagnostic and treatment algorithm developed by the authors of this manuscript, which is largely based on the one proposed above, is intended to address the current lack of specific guidelines for the differential diagnosis and management of Pa-CKD in Spain.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Conflict of interest</span><p id="par0155" class="elsevierStylePara elsevierViewall">All authors have received honoraria for report or consultancies from CSL-VIFOR.</p></span></span>"
"textoCompletoSecciones" => array:1 [
"secciones" => array:10 [
0 => array:3 [
"identificador" => "xres2230887"
"titulo" => "Abstract"
"secciones" => array:1 [
0 => array:1 [
"identificador" => "abst0005"
]
]
]
1 => array:2 [
"identificador" => "xpalclavsec1868113"
"titulo" => "Keywords"
]
2 => array:3 [
"identificador" => "xres2230886"
"titulo" => "Resumen"
"secciones" => array:1 [
0 => array:1 [
"identificador" => "abst0010"
]
]
]
3 => array:2 [
"identificador" => "xpalclavsec1868112"
"titulo" => "Palabras clave"
]
4 => array:2 [
"identificador" => "sec0005"
"titulo" => "Introduction"
]
5 => array:2 [
"identificador" => "sec0010"
"titulo" => "Methodology"
]
6 => array:3 [
"identificador" => "sec0015"
"titulo" => "Results"
"secciones" => array:4 [
0 => array:2 [
"identificador" => "sec0020"
"titulo" => "Screening"
]
1 => array:2 [
"identificador" => "sec0025"
"titulo" => "Differential diagnosis"
]
2 => array:2 [
"identificador" => "sec0030"
"titulo" => "Registration"
]
3 => array:2 [
"identificador" => "sec0035"
"titulo" => "Treatment and follow-up"
]
]
]
7 => array:2 [
"identificador" => "sec0040"
"titulo" => "Discussion"
]
8 => array:2 [
"identificador" => "sec0045"
"titulo" => "Conflict of interest"
]
9 => array:1 [
"titulo" => "References"
]
]
]
"pdfFichero" => "main.pdf"
"tienePdf" => true
"fechaRecibido" => "2023-02-21"
"fechaAceptado" => "2023-04-17"
"PalabrasClave" => array:2 [
"en" => array:1 [
0 => array:4 [
"clase" => "keyword"
"titulo" => "Keywords"
"identificador" => "xpalclavsec1868113"
"palabras" => array:5 [
0 => "Pruritus"
1 => "Kidney failure, chronic"
2 => "Diagnostic"
3 => "Treatment"
4 => "Hemodialysis"
]
]
]
"es" => array:1 [
0 => array:4 [
"clase" => "keyword"
"titulo" => "Palabras clave"
"identificador" => "xpalclavsec1868112"
"palabras" => array:5 [
0 => "Prurito"
1 => "Enfermedad renal crónica"
2 => "Diagnóstico"
3 => "Tratamiento"
4 => "Hemodiálisis"
]
]
]
]
"tieneResumen" => true
"resumen" => array:2 [
"en" => array:2 [
"titulo" => "Abstract"
"resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Chronic kidney disease-associated pruritus (CKD-aP) is one of the most common and disabling comorbidities in patients with advanced CKD. In addition, it is associated with an increased risk of mortality, poorer quality of life, sleep disorders, mental health disorders, and increased use of health care resources. The clinical presentation of CKD-aP is very heterogeneous, making it difficult to diagnose and treat. Currently, there are no national guidelines on the management of CKD-aP.</p><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">The aim of this document is to provide national consensus recommendations for the diagnostic and therapeutic management of CKD-aP.</p><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">The document was prepared in three phases: a diagnostic and therapeutic management algorithm was proposed by a small group of nephrology specialists; the proposal was validated by a larger group of nephrologists; and a second validation by a multidisciplinary group that also included dermatology specialists.</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">The diagnostic and therapeutic management algorithm attempts to cover the current need of a lack of specific guidelines for the adequate management of CKD-aP. At the same time, it introduces the use of difelikefalin, the first and only drug specifically approved for CKD-aP, with a good safety and efficacy profile.</p></span>"
]
"es" => array:2 [
"titulo" => "Resumen"
"resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">El prurito asociado a la enfermedad renal crónica (Pa-ERC), es una de las comorbilidades más comunes e incapacitantes en los pacientes con ERC avanzada. Además, está asociado a un mayor riesgo de mortalidad, peor calidad de vida, aparición de trastornos del sueño, alteraciones de la salud mental y mayor uso de recursos sanitarios. La presentación clínica del Pa-ERC es muy heterogénea, lo que dificulta su diagnóstico y su tratamiento. Actualmente, no existen guías a nivel nacional sobre el manejo del Pa-ERC.</p><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">El objetivo de este documento es proporcionar unas recomendaciones de consenso a nivel nacional para el manejo diagnóstico y terapéutico del Pa-ERC.</p><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">La elaboración del documento se realizó en tres fases: la realización de una propuesta de algoritmo de manejo diagnóstico y terapéutico por parte de un grupo reducido de especialistas en nefrología; la validación de la propuesta por un grupo más amplio de nefrólogos y, finalmente, una segunda validación por un grupo multidisciplinar en el que se incluyeron, además, especialistas en dermatología.</p><p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">El algoritmo de manejo diagnóstico y terapéutico trata de cubrir la actual necesidad por una falta de directrices específicas para el control adecuado del Pa-ERC en España. A la vez, introduce el uso de difelicefalina, el primer y único fármaco aprobado específicamente para el Pa-ERC de pacientes en hemodiálisis, con un buen perfil de seguridad y eficacia.</p></span>"
]
]
"NotaPie" => array:2 [
0 => array:3 [
"etiqueta" => "1"
"nota" => "<p class="elsevierStyleNotepara" id="npar0005">The names of the nephrologists who are members of the Spanish Group of Pruritus Associated with CKD are listed in Appendix Banexo 1.</p>"
"identificador" => "fn0005"
]
1 => array:3 [
"etiqueta" => "1"
"nota" => "<p class="elsevierStyleNotepara" id="npar0010">At the time of writing, difelicefalin was not available in Spain, although it was available as an early use program.</p>"
"identificador" => "fn0010"
]
]
"apendice" => array:1 [
0 => array:1 [
"seccion" => array:1 [
0 => array:4 [
"apendice" => "<p id="par0165" class="elsevierStylePara elsevierViewall">The following is Supplementary data to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>"
"etiqueta" => "Appendix A"
"titulo" => "Supplementary data"
"identificador" => "sec0055"
]
]
]
]
"multimedia" => array:10 [
0 => array:8 [
"identificador" => "fig0005"
"etiqueta" => "Fig. 1"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr1.jpeg"
"Alto" => 4341
"Ancho" => 3164
"Tamanyo" => 987215
]
]
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0005"
"detalle" => "Fig. "
"rol" => "short"
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Algorithm for diagnostic and therapeutic management of Pa-CKD in hemodialysis patients.</p>"
]
]
1 => array:8 [
"identificador" => "fig0010"
"etiqueta" => "Fig. 2"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr2.jpeg"
"Alto" => 1982
"Ancho" => 2925
"Tamanyo" => 438469
]
]
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0010"
"detalle" => "Fig. "
"rol" => "short"
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Classification of pruritus according to the IFSI in two steps.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a></p>"
]
]
2 => array:8 [
"identificador" => "fig0015"
"etiqueta" => "Fig. 3"
"tipo" => "MULTIMEDIAFIGURA"
"mostrarFloat" => true
"mostrarDisplay" => false
"figura" => array:1 [
0 => array:4 [
"imagen" => "gr3.jpeg"
"Alto" => 2350
"Ancho" => 2925
"Tamanyo" => 669664
]
]
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0015"
"detalle" => "Fig. "
"rol" => "short"
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Suggested assessment scales for measuring the severity of itching.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,15</span></a></p>"
]
]
3 => array:8 [
"identificador" => "tbl0005"
"etiqueta" => "Table 1"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0020"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:1 [
"tablatextoimagen" => array:1 [
0 => array:2 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Phase \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recommendations \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Level of evidence \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Screening \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">1. It is recommended that the initial screening be performed by the nephrologist or nursing professional and use only question 20 of the KDQoL-36: "In the last 4 weeks, to what extent have you felt discomfort caused by itching". \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Differential diagnosis \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">2. It is recommended to perform a skin examination of the patient, at the clinic, to verify the presence of lesions on the patient's skin and to rule out those not attributable to Pa-CKD. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">3. In case of the presence of primary skin lesions not attributable to Pa-CKD, it is recommended referral to dermatology. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">4. If no lesions are visualized or if they are secondary, it is also recommended to rule out other potential causes of active pruritus in the patient and if there are any, refer to the corresponding specialist. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">5. If there are no primary lesions or other causes associated with pruritus, it is recommended to consider the diagnosis of Pa-CKD. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">6. If Pa-CKD is diagnosed, it is recommended an assessment of the intensity and severity of pruritus using the WI-NRS and SADS questionnaires. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Registration \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">7. It is recommended that the healthcare professional register the patient diagnosed with Pa-CKD in the computer system, using the coding of the pathology, with the tools currently available (ICD-9, ICD-10) until ICD-11 is available. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Treatment and follow-up \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">8. For the treatment of mild Pa-CKD, general measures such as skin hydration, maintenance of barrier function and other skin care techniques are recommended. In addition, adequate dialysis efficacy and control of calcium-phosphorus metabolism should be ensured. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">9. For the treatment of moderate to severe Pa-CKD, it is recommended to use specific therapy for itching, being difelicefalin the only drug with specific indication approved for Pa-CKD in hemodialysis patients. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Based on clinical trials \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">10. For the treatment of moderate to severe Pa-CKD, the off-label use of gabapentinoids, mirtazapine and/or montelukast could be considered. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">11. Once treatment for Pa-CKD has been initiated, it is recommended that the intensity of pruritus be monitored (using the WI-NRS and SADS questionnaires) at least at 3 months. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">12. If after 3 months of treatment, the patient suffers severe side effects or no improvement, it is recommended to consider re-evaluating the treatment. \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Expert opinion \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
"imagenFichero" => array:1 [
0 => "xTab3637198.png"
]
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Recommendations for the diagnosis and treatment of Pa-CKD.</p>"
]
]
4 => array:8 [
"identificador" => "tbl0010"
"etiqueta" => "Table 2"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0025"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:1 [
"tablatextoimagen" => array:1 [
0 => array:2 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">WI-NRS questionnaire score \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Intensity of itching \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">NRS = 0 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">No itching \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">NRS ≥ 3 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Mild itching \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">NRS ≥4 < 7 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Moderate itching \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">NRS ≥7 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Severe itching \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
"imagenFichero" => array:1 [
0 => "xTab3637196.png"
]
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Assessment of the intensity of itching.</p>"
]
]
5 => array:8 [
"identificador" => "tbl0015"
"etiqueta" => "Table 3"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0030"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:1 [
"tablatextoimagen" => array:2 [
0 => array:2 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " colspan="9" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Search coding by ICD</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">CIE \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Search \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="4" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Tabular list</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="3" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Select</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">ICD-9-CM \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">698.9 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Tab.D</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Ch.12 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">690−698 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">698.9</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Unspecified pruritic disorders \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">ICD-10-CM \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">L29.9 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Tab.D</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Ch.12 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">L20-L30 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">L29.9</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Itching, unspecified \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
"imagenFichero" => array:1 [
0 => "xTab3637194.png"
]
]
1 => array:2 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " colspan="9" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Direct mapping</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Code \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Classification origin</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="4" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Destination classification</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Select</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">L29.9 \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">ICD-10-EN Diag.</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="4" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">ICD-9-CM</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " colspan="2" align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">698.9 Unspecified pruritic diseases</td></tr></tbody></table>
"""
]
"imagenFichero" => array:1 [
0 => "xTab3637195.png"
]
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Diagnostic coding.</p>"
]
]
6 => array:9 [
"identificador" => "tbl0020"
"etiqueta" => "Table 4"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"fuente" => "Source: Kang et al.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">34</span></a>"
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0035"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:1 [
"tablatextoimagen" => array:1 [
0 => array:2 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pa-CKD Patient Skin Care Guide \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">- Moisturize skin daily or twice daily, especially after showers/baths. \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Apply emollients, especially at night: \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">◦ Creams \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">◦ Lotions \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">◦ Gels \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Considerations to take into account \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- The term "moisturizer" includes emollients, humectants and occlusives: \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Emollients: improve skin barrier function, membrane fluidity and cell signaling, resulting in an overall improvement in skin texture and appearance. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Humectants: attract water to the stratum corneum. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Occlusives: form a layer on the skin surface to physically block evaporation of water from the skin. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Moisturizer and emollient are often used interchangeably; however, moisturizers often contain humectants to hydrate the stratum corneum of the skin. \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
"imagenFichero" => array:1 [
0 => "xTab3637192.png"
]
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Emollients and moisturizers for pruritus associated with CKD.</p>"
]
]
7 => array:8 [
"identificador" => "tbl0025"
"etiqueta" => "Table 5"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0040"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:1 [
"tablatextoimagen" => array:1 [
0 => array:2 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Skin care</span> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Wear permeable and soft clothing, e.g., cotton; dress in several layers to avoid sweating. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Keep room temperature low overnight \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Use mild, non-alkaline, fragrance-free soaps and bath oils. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Moisturize skin daily, especially after showering/bathing. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Apply emollients, especially at night. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Creams/lotions/gels \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Apply refreshing wet wraps \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Limit baths to 20 min \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Use lukewarm water ± oatmeal or potassium permanganate; pat the skin dry. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Avoid</span> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Factors that may contribute to skin dryness \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Excitement, tension, negative stress \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Very hot and spicy foods, large quantities of hot beverages and alcohol \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Contact with allergenic and irritating substances \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"><span class="elsevierStyleItalic">Others</span> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Relaxation techniques: Autogenic training, relaxation therapy, psychosocial education. \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">- Education: Coping with the vicious circle of \n
<itch-scratch-itch>\n
.\n
</itch-scratch-itch> \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
"imagenFichero" => array:1 [
0 => "xTab3637197.png"
]
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">General advice for the management of pruritus associated with chronic kidney disease.</p>"
]
]
8 => array:8 [
"identificador" => "tbl0030"
"etiqueta" => "Table 6"
"tipo" => "MULTIMEDIATABLA"
"mostrarFloat" => true
"mostrarDisplay" => false
"detalles" => array:1 [
0 => array:3 [
"identificador" => "at0045"
"detalle" => "Table "
"rol" => "short"
]
]
"tabla" => array:1 [
"tablatextoimagen" => array:1 [
0 => array:2 [
"tabla" => array:1 [
0 => """
<table border="0" frame="\n
\t\t\t\t\tvoid\n
\t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Gabapentin<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Mirtazapine<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Montelukast<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th><th class="td" title="\n
\t\t\t\t\ttable-head\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t" scope="col" style="border-bottom: 2px solid black">Difelicefalin<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> \t\t\t\t\t\t\n
\t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Infections and infestations \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Viral infection, pneumonia, respiratory infection, urinary tract infection, infection, otitis media \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Blood disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Leukopenia \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Immune system disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Allergic reactions (e.g., urticaria) \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Metabolic and nutritional disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Anorexia, increased appetite \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Increased appetite, weight gain \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Psychiatric disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Hostility, emotional turmoil and instability, depression, anxiety, nervousness, abnormal thinking \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Abnormal dreams, confusion, anxiety, insomnia \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Nervous system disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Drowsiness, dizziness, ataxia, seizures, hyperkinesia, dysarthria, amnesia, tremor, insomnia, headache, sensations such as paresthesia, hyposthesia, abnormal coordination, nystagmus, increased/decreased/absent reflexes \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">drowsiness, sedation, headache, lethargy, dizziness, tremor, amnesia \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Headache \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Drowsiness, paresthesia \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Ocular disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Amblyopia, diplopia \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Ear and labyrinth disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Vertigo \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Vascular disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Hypertension, vasodilatation \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Orthostatic hypotension \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Respiratory, thoracic and mediastinal disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Dyspnea, bronchitis, pharyngitis, cough, rhinitis \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Gastrointestinal disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Vomiting, nausea, dental abnormalities, gingivitis, diarrhea, abdominal pain, dyspepsia, constipation, dry mouth or dry throat, flatulence \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Dry mouth, nausea, nausea, diarrhea, vomiting, constipation \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Abdominal pain \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Skin and subcutaneous tissue disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Facial edema, purpura most often described as contusions resulting from physical trauma, rash, pruritus, acne \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Exanthema \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Musculoskeletal and connective tissue disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Arthralgia, myalgia, back pain, spasms, spasms \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Arthralgia, myalgia, back pain \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Renal and urinary disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Impotence \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">General disorders \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Fatigue, fever, peripheral edema, abnormal gait, asthenia, pain, malaise, flu-like syndrome \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t">Peripheral edema, fatigue \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td><td class="td" title="\n
\t\t\t\t\ttable-entry\n
\t\t\t\t " align="left" valign="\n
\t\t\t\t\ttop\n
\t\t\t\t"> \t\t\t\t\t\t\n
\t\t\t\t</td></tr></tbody></table>
"""
]
"imagenFichero" => array:1 [
0 => "xTab3637193.png"
]
]
]
]
"descripcion" => array:1 [
"en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Very frequent and frequent adverse reactions according to the technical data sheet of the drugs used to treat Pa-CKD.</p>"
]
]
9 => array:5 [
"identificador" => "upi0005"
"tipo" => "MULTIMEDIAECOMPONENTE"
"mostrarFloat" => false
"mostrarDisplay" => true
"Ecomponente" => array:2 [
"fichero" => "mmc1.docx"
"ficheroTamanyo" => 10865957
]
]
]
"bibliografia" => array:2 [
"titulo" => "References"
"seccion" => array:1 [
0 => array:2 [
"identificador" => "bibs0005"
"bibliografiaReferencia" => array:38 [
0 => array:3 [
"identificador" => "bib0005"
"etiqueta" => "1"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Uremic pruritus"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:2 [
0 => "T. Mettang"
1 => "A.E. Kremer"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1038/ki.2013.454"
"Revista" => array:7 [
"tituloSerie" => "Kidney Int."
"fecha" => "2015"
"volumen" => "87"
"numero" => "4"
"paginaInicial" => "685"
"paginaFinal" => "691"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/24402092"
"web" => "Medline"
]
]
]
]
]
]
]
]
1 => array:3 [
"identificador" => "bib0010"
"etiqueta" => "2"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "CIE-11 para estadísticas de mortalidad y morbilidad [Internet]. [cited 2022 Aug 11]. Available from: <a target="_blank" href="https://icd.who.int/browse11/l-m/es#/http://id.who.int/icd/entity/2094665806">https://icd.who.int/browse11/l-m/es#/http://id.who.int/icd/entity/2094665806</a>."
]
]
]
2 => array:3 [
"identificador" => "bib0015"
"etiqueta" => "3"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "Hemodialysis-associated pruritus (disorder) [Internet]. [cited 2022 Sep 12]. Available from: <a target="_blank" href="https://snomedbrowser.com/Codes/Details/403733004">https://snomedbrowser.com/Codes/Details/403733004</a>."
]
]
]
3 => array:3 [
"identificador" => "bib0020"
"etiqueta" => "4"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "Páginas - REGISTRO ESPAÑOL DE ENFERMOS RENALES [Internet]. [cited 2022 May 13]. Available from: <a target="_blank" href="http://www.ont.es/infesp/Paginas/RegistroEnfermosRenales.aspx">http://www.ont.es/infesp/Paginas/RegistroEnfermosRenales.aspx</a>."
]
]
]
4 => array:3 [
"identificador" => "bib0025"
"etiqueta" => "5"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "R.L. Pisoni"
1 => "B. Wikström"
2 => "S.J. Elder"
3 => "T. Akizawa"
4 => "Y. Asano"
5 => "M.L. Keen"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:6 [
"tituloSerie" => "Nephrol Dialysis Transplant."
"fecha" => "2006"
"volumen" => "21"
"numero" => "12"
"paginaInicial" => "3495"
"paginaFinal" => "3505"
]
]
]
]
]
]
5 => array:3 [
"identificador" => "bib0030"
"etiqueta" => "6"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Prevalence and severity of pruritus in Spanish patients with chronic kidney disease and impact on quality of life: a cross-sectional study"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "N. Aresté"
1 => "J.E. Sanchez-Alvarez"
2 => "M. Prieto-Velasco"
3 => "P. Molina"
4 => "V. Esteve-Simó"
5 => "R. Ojeda"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:6 [
"tituloSerie" => "Clin Kidney J."
"fecha" => "2023"
"volumen" => "0"
"numero" => "0"
"paginaInicial" => "1"
"paginaFinal" => "3"
]
]
]
]
]
]
6 => array:3 [
"identificador" => "bib0035"
"etiqueta" => "7"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "A Survey on the Impact of Pruritus Associated With Chronic Kidney Disease (CKD-AP) In the Quality of Life of Patients Undergoing Haemodialysis in Spain"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "V. Reyes"
1 => "J. Caro"
2 => "B. Pais"
3 => "F.J.M. Buades"
4 => "P. de Sequera Ortiz"
5 => "J. Espín"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Libro" => array:2 [
"fecha" => "2022"
"editorial" => "In: 59th ERA Congress"
]
]
]
]
]
]
7 => array:3 [
"identificador" => "bib0040"
"etiqueta" => "8"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Chronic kidney disease-associated pruritus: a review"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:3 [
0 => "M. Makar"
1 => "B. Smyth"
2 => "F. Brennan"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1159/000518391"
"Revista" => array:7 [
"tituloSerie" => "Kidney Blood Press Res."
"fecha" => "2021"
"volumen" => "46"
"numero" => "6"
"paginaInicial" => "659"
"paginaFinal" => "669"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/34515143"
"web" => "Medline"
]
]
]
]
]
]
]
]
8 => array:3 [
"identificador" => "bib0045"
"etiqueta" => "9"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "European S2k guideline on chronic pruritus"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "E. Weisshaar"
1 => "J.C. Szepietowski"
2 => "F.J. Dalgard"
3 => "S. Garcovich"
4 => "U. Gieler"
5 => "A.M. Giménez-Arnau"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.2340/00015555-3164"
"Revista" => array:7 [
"tituloSerie" => "Acta Derm Venereol."
"fecha" => "2019"
"volumen" => "99"
"numero" => "5"
"paginaInicial" => "469"
"paginaFinal" => "506"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/30931482"
"web" => "Medline"
]
]
]
]
]
]
]
]
9 => array:3 [
"identificador" => "bib0050"
"etiqueta" => "10"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:2 [
0 => "J. Topf"
1 => "T. Wooldridge"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:4 [
"tituloSerie" => "Kidney Med."
"fecha" => "2022"
"volumen" => "4"
"numero" => "8"
]
]
]
]
]
]
10 => array:3 [
"identificador" => "bib0055"
"etiqueta" => "11"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "CHMP. Committee for Medicinal Products for Human Use (CHMP) Assessment report. 2022 [cited 2022 Oct 13]; Available from: <a target="_blank" href="http://www.ema.europa.eu/contact">www.ema.europa.eu/contact</a>."
]
]
]
11 => array:3 [
"identificador" => "bib0060"
"etiqueta" => "12"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "CHMP. ANEXO I FICHA TÉCNICA O. RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO; KAPRUVIA."
]
]
]
12 => array:3 [
"identificador" => "bib0065"
"etiqueta" => "13"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:5 [
0 => "M. Vernon"
1 => "S. Ständer"
2 => "C. Munera"
3 => "R.H. Spencer"
4 => "F. Menzaghi"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1016/j.jaad.2020.06.991"
"Revista" => array:7 [
"tituloSerie" => "J Am Acad Dermatol."
"fecha" => "2021"
"volumen" => "84"
"numero" => "4"
"paginaInicial" => "1132"
"paginaFinal" => "1134"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/32603719"
"web" => "Medline"
]
]
]
]
]
]
]
]
13 => array:3 [
"identificador" => "bib0070"
"etiqueta" => "14"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "N.Q. Phan"
1 => "C. Blome"
2 => "F. Fritz"
3 => "J. Gerss"
4 => "A. Reich"
5 => "T. Ebata"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.2340/00015555-1246"
"Revista" => array:7 [
"tituloSerie" => "Acta Derm Venereol."
"fecha" => "2012"
"volumen" => "92"
"numero" => "5"
"paginaInicial" => "502"
"paginaFinal" => "507"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/22170091"
"web" => "Medline"
]
]
]
]
]
]
]
]
14 => array:3 [
"identificador" => "bib0075"
"etiqueta" => "15"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "A longitudinal study of uremic pruritus in hemodialysis patients"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "V.S. Mathur"
1 => "J. Lindberg"
2 => "M. Germain"
3 => "G. Block"
4 => "J. Tumlin"
5 => "M. Smith"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.2215/CJN.00100110"
"Revista" => array:7 [
"tituloSerie" => "Clin J Am Soc Nephrol."
"fecha" => "2010"
"volumen" => "5"
"numero" => "8"
"paginaInicial" => "1410"
"paginaFinal" => "1419"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/20558560"
"web" => "Medline"
]
]
]
]
]
]
]
]
15 => array:3 [
"identificador" => "bib0080"
"etiqueta" => "16"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Validation of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) US Spanish and English versions in a cohort of Hispanics with chronic kidney disease"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "A.C. Ricardo"
1 => "E. Hacker"
2 => "C.M. Lora"
3 => "L. Ackerson"
4 => "K.B. De Salvo"
5 => "A. Go"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:7 [
"tituloSerie" => "Ethn Dis."
"fecha" => "2013"
"volumen" => "23"
"numero" => "2"
"paginaInicial" => "202"
"paginaFinal" => "209"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/23530302"
"web" => "Medline"
]
]
]
]
]
]
]
]
16 => array:3 [
"identificador" => "bib0085"
"etiqueta" => "17"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "CIE-11 para estadísticas de mortalidad y morbilidad [Internet]. [cited 2022 Sep 12]. Available from: <a target="_blank" href="https://icd.who.int/browse11/l-m/es#/http://id.who.int/icd/entity/2094665806">https://icd.who.int/browse11/l-m/es#/http://id.who.int/icd/entity/2094665806</a>."
]
]
]
17 => array:3 [
"identificador" => "bib0090"
"etiqueta" => "18"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "CIE 9 Clasificación Internacional de Enfermedades [Internet]. 2013 [cited 2023 Jan 9]. Available from: <a target="_blank" href="https://www.sanidad.gob.es/estadEstudios/estadisticas/docs/CIE9MC_2014_def_accesible.pdf">https://www.sanidad.gob.es/estadEstudios/estadisticas/docs/CIE9MC_2014_def_accesible.pdf</a>."
]
]
]
18 => array:3 [
"identificador" => "bib0095"
"etiqueta" => "19"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:3 [
0 => "T. Lau"
1 => "S. Leung"
2 => "W. Lau"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:4 [
"tituloSerie" => "Can J Kidney Health Dis"
"fecha" => "2016"
"volumen" => "3"
"numero" => "14"
]
]
]
]
]
]
19 => array:3 [
"identificador" => "bib0100"
"etiqueta" => "20"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Percepción de los nefrólogos españoles sobre un problema antiguo no resuelto: Prurito asociado a la enfermedad renal crónica (Pa-ERC)"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "M. Goicoechea"
1 => "M.D. Arenas-Jimenez"
2 => "N. Areste"
3 => "R.E. Perez-Morales"
4 => "V. Esteve"
5 => "E. Sanchez-Alvarez"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1016/j.nefroe.2023.03.012"
"Revista" => array:7 [
"tituloSerie" => "Nefrología."
"fecha" => "2023"
"volumen" => "43"
"numero" => "1"
"paginaInicial" => "102"
"paginaFinal" => "110"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/37069038"
"web" => "Medline"
]
]
]
]
]
]
]
]
20 => array:3 [
"identificador" => "bib0105"
"etiqueta" => "21"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "Gabapentin FDA prescribing information [Internet]. [cited 2023 Jan 9]. Available from: <a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf</a>."
]
]
]
21 => array:3 [
"identificador" => "bib0110"
"etiqueta" => "22"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "Boletín mensual de seguridad de la AEMPS sobre medicamentos de uso humano del mes de octubre de 2022 | Agencia Española de Medicamentos y Productos Sanitarios [Internet]. [cited 2023 Jan 9]. Available from: <a target="_blank" href="https://www.aemps.gob.es/informa/boletin-mensual-de-seguridad-de-la-aemps-sobre-medicamentos-de-uso-humano-del-mes-de-octubre-de-2022/">https://www.aemps.gob.es/informa/boletin-mensual-de-seguridad-de-la-aemps-sobre-medicamentos-de-uso-humano-del-mes-de-octubre-de-2022/</a>."
]
]
]
22 => array:3 [
"identificador" => "bib0115"
"etiqueta" => "23"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April - GOV.UK [Internet]. [cited 2023 Jan 9]. Available from: <a target="_blank" href="https://www.gov.uk/drug-safety-update/pregabalin-lyrica-gabapentin-neurontin-and-risk-of-abuse-and-dependence-new-scheduling-requirements-from-1-april#risk-of-abuse-and-dependence">https://www.gov.uk/drug-safety-update/pregabalin-lyrica-gabapentin-neurontin-and-risk-of-abuse-and-dependence-new-scheduling-requirements-from-1-april#risk-of-abuse-and-dependence</a>."
]
]
]
23 => array:3 [
"identificador" => "bib0120"
"etiqueta" => "24"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Gabapentinoid abuse in france: evidence on health consequences and new points of vigilance"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:6 [
0 => "M. Tambon"
1 => "C. Ponté"
2 => "E. Jouanjus"
3 => "N. Fouilhé"
4 => "J. Micallef"
5 => "M. Lapeyre-Mestre"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:5 [
"tituloSerie" => "Front Psychiatry."
"fecha" => "2021 Feb"
"volumen" => "3"
"numero" => "12"
"paginaInicial" => "37"
]
]
]
]
]
]
24 => array:3 [
"identificador" => "bib0125"
"etiqueta" => "25"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:6 [
0 => "M. Mahmudpour"
1 => "J. Rouzbeh"
2 => "Q.A.R. Jalali"
3 => "M. Pakfetrat"
4 => "S. Ezzatzadegan"
5 => "M.M. Sagheb"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:7 [
"tituloSerie" => "Iran J Kidney Dis."
"fecha" => "2017"
"volumen" => "11"
"numero" => "1"
"paginaInicial" => "50"
"paginaFinal" => "55"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/28174353"
"web" => "Medline"
]
]
]
]
]
]
]
]
25 => array:3 [
"identificador" => "bib0130"
"etiqueta" => "26"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Montelukast for treatment of refractory pruritus in patients on hemodialysis"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:5 [
0 => "A.R. Nasrollahi"
1 => "A. Miladipour"
2 => "E. Ghanei"
3 => "P. Yavari"
4 => "F. Haghverdi"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:8 [
"tituloSerie" => "Iran J Kidney Dis."
"fecha" => "2007"
"volumen" => "1"
"numero" => "2"
"paginaInicial" => "73"
"paginaFinal" => "77"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/37060340"
"web" => "Medline"
]
]
"itemHostRev" => array:3 [
"pii" => "S0021755717302188"
"estado" => "S300"
"issn" => "00217557"
]
]
]
]
]
]
]
26 => array:3 [
"identificador" => "bib0135"
"etiqueta" => "27"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:6 [
0 => "M. Gholyaf"
1 => "V. Sheikh"
2 => "F. Yasrebifar"
3 => "Y. Mohammadi"
4 => "M. Mirjalili"
5 => "M. Mehrpooya"
]
]
]
]
]
"host" => array:2 [
0 => array:2 [
"doi" => "10.1007/s11255-020-02473-3"
"Revista" => array:7 [
"tituloSerie" => "Int Urol Nephrol [Internet]"
"fecha" => "2020"
"volumen" => "52"
"numero" => "6"
"paginaInicial" => "1155"
"paginaFinal" => "1165"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/32383050"
"web" => "Medline"
]
]
]
]
1 => array:2 [
"doi" => "10.1007/s11255-020-02473-3"
"WWW" => array:1 [
"link" => "https://link.springer.com/article/10.1007/s11255-020-02473-3"
]
]
]
]
]
]
27 => array:3 [
"identificador" => "bib0140"
"etiqueta" => "28"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "Internacional C. CIE • 10 • ES Tomo I: Diagnósticos INFORMACIÓN Y ESTADÍSTICAS SANITARIAS 2020 MINISTERIO DE SANIDAD, CONSUMO Y BIENESTAR SOCIAL MINISTERIO DE LA PRESIDENCIA, RELACIONES CON LAS CORTES E IGUALDAD BOLETÍN OFICIAL DEL ESTADO. [cited 2022 Oct 13]; Available from: <a target="_blank" href="http://eciemaps.mcsb.gob.es/ecieMaps/errata/errata.html">http://eciemaps.mcsb.gob.es/ecieMaps/errata/errata.html</a>."
]
]
]
28 => array:3 [
"identificador" => "bib0145"
"etiqueta" => "29"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Prurito en pacientes en diálisis. Revisión de la literatura y nuevas perspectivas"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:3 [
0 => "C. Santos-Alonso"
1 => "M. Maldonaldo Martín"
2 => "R. Sánchez Villanueva"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:2 [
"tituloSerie" => "Nefrología."
"fecha" => "2021"
]
]
]
]
]
]
29 => array:3 [
"identificador" => "bib0150"
"etiqueta" => "30"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "S. Fishbane"
1 => "V. Mathur"
2 => "M.J. Germain"
3 => "S. Shirazian"
4 => "S. Bhaduri"
5 => "C. Munera"
]
]
]
]
]
"host" => array:1 [
0 => array:2 [
"doi" => "10.1016/j.ekir.2020.01.006"
"Revista" => array:7 [
"tituloSerie" => "Kidney Int Rep."
"fecha" => "2020"
"volumen" => "5"
"numero" => "5"
"paginaInicial" => "600"
"paginaFinal" => "610"
"link" => array:1 [
0 => array:2 [
"url" => "https://www.ncbi.nlm.nih.gov/pubmed/32405581"
"web" => "Medline"
]
]
]
]
]
]
]
]
30 => array:3 [
"identificador" => "bib0155"
"etiqueta" => "31"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "S2k-Leitlinie. [cited 2022 Nov 28]; Available from: <a target="_blank" href="https://www.awmf.org/leitlinien/detail/ll/013-048.html">https://www.awmf.org/leitlinien/detail/ll/013-048.html</a>."
]
]
]
31 => array:3 [
"identificador" => "bib0160"
"etiqueta" => "32"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Alleviating symptoms in patients undergoing long-term hemodialysis: a focus on chronic kidney disease-associated pruritus"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "R. Agarwal"
1 => "J. Burton"
2 => "M. Gallieni"
3 => "K. Kalantar-Zadeh"
4 => "G. Mayer"
5 => "C. Pollock"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:6 [
"tituloSerie" => "Clin Kidney J [Internet]"
"fecha" => "2022"
"volumen" => "0"
"numero" => "0"
"paginaInicial" => "1"
"paginaFinal" => "11"
]
]
]
]
]
]
32 => array:3 [
"identificador" => "bib0165"
"etiqueta" => "33"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "A phase 3 trial of difelikefalin in hemodialysis patients with pruritus"
"autores" => array:1 [
0 => array:2 [
"etal" => false
"autores" => array:5 [
0 => "S. Fishbane"
1 => "A. Jamal"
2 => "C. Munerea"
3 => "W. Wen"
4 => "F. Menzaghi"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:4 [
"tituloSerie" => "N Engl J Med."
"fecha" => "2020"
"volumen" => "282"
"numero" => "3"
]
]
]
]
]
]
33 => array:3 [
"identificador" => "bib0170"
"etiqueta" => "34"
"referencia" => array:1 [
0 => array:2 [
"contribucion" => array:1 [
0 => array:2 [
"titulo" => "Moisturizer in patients with inflammatory skin diseases"
"autores" => array:1 [
0 => array:2 [
"etal" => true
"autores" => array:6 [
0 => "S.Y. Kang"
1 => "J.Y. Um"
2 => "B.Y. Chung"
3 => "S.Y. Lee"
4 => "J.S. Park"
5 => "J.C. Kim"
]
]
]
]
]
"host" => array:1 [
0 => array:1 [
"Revista" => array:4 [
"tituloSerie" => "Medicina (B Aires)."
"fecha" => "2022"
"volumen" => "58"
"numero" => "7"
]
]
]
]
]
]
34 => array:3 [
"identificador" => "bib0175"
"etiqueta" => "35"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "FICHA TECNICA GABAPENTINA SANDOZ 300 mg CAPSULAS DURAS EFG [Internet]. [cited 2022 Nov 24]. Available from: <a target="_blank" href="https://cima.aemps.es/cima/dochtml/ft/69823/FT_69823.html#4-8-reacciones-adversas">https://cima.aemps.es/cima/dochtml/ft/69823/FT_69823.html#4-8-reacciones-adversas</a>."
]
]
]
35 => array:3 [
"identificador" => "bib0180"
"etiqueta" => "36"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "FICHA TECNICA MIRTAZAPINA CINFA 30 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG [Internet]. [cited 2022 Nov 24]. Available from: <a target="_blank" href="https://cima.aemps.es/cima/dochtml/ft/67068/FT_67068.html#4-8-reacciones-adversas">https://cima.aemps.es/cima/dochtml/ft/67068/FT_67068.html#4-8-reacciones-adversas</a>."
]
]
]
36 => array:3 [
"identificador" => "bib0185"
"etiqueta" => "37"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "FICHA TECNICA MONTELUKAST TEVA 10 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG [Internet]. [cited 2022 Nov 28]. Available from: <a target="_blank" href="https://cima.aemps.es/cima/dochtml/ft/70888/FichaTecnica_70888.html">https://cima.aemps.es/cima/dochtml/ft/70888/FichaTecnica_70888.html</a>."
]
]
]
37 => array:3 [
"identificador" => "bib0190"
"etiqueta" => "38"
"referencia" => array:1 [
0 => array:1 [
"referenciaCompleta" => "CHMP. Anexo I ficha técnica o resumen de las características del producto."
]
]
]
]
]
]
]
]
"idiomaDefecto" => "en"
"url" => "/20132514/0000004400000004/v1_202408300447/S2013251424001342/v1_202408300447/en/main.assets"
"Apartado" => array:4 [
"identificador" => "97793"
"tipo" => "SECCION"
"en" => array:2 [
"titulo" => "Review articles"
"idiomaDefecto" => true
]
"idiomaDefecto" => "en"
]
"PDF" => "https://static.elsevier.es/multimedia/20132514/0000004400000004/v1_202408300447/S2013251424001342/v1_202408300447/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
"EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251424001342?idApp=UINPBA000064"
]
